Malignant tumors and other diseases
Conditions
Interventions
Index test:PET imaging with a novel targeted tumor stromal fibroblast activation protein tracers
Sponsors
Nanfang Hospital, Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-70 years, no gender limit; 2. Tumor subjects or suspected tumor subjects who plan to undergo pathological biopsy or receive tumor surgical treatment recently (within 2 months); 3. Expected survival >=12 weeks; 4. Blood routine, liver and kidney function meet the following criteria: Blood routine: WBC>=4.0x10^9L or neutrophil >=1.5x10^9L, PLT>=100x10^9/L, Hb>=90g/L; PT or APTT<=1.5ULN; Liver and kidney function: T-Bil<=1.5xULT(upper limit of normal), ALT/AST<=2.5ULN or <=5xULT(subjects with liver metastasis), ALP<=2.5ULN(ALP<= 4.5ULN if bone metastasis or liver metastasis existed); BUN<=1.5xULT, SCr<=1.5xULT; 5. There is at least one measurable target lesion according to RECIST1.1 standard; 6. Understand and voluntarily sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Dying emergency patients, respiratory depression, airway obstruction or tissue hypoxia; 2. Drug and/or alcohol abusers, allergic patients; 3. Prepare for pregnancy, pregnant and lactating patients; 4. Those who cannot tolerate and cooperate with the test; 5. The researcher judged that it was not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity and specificity of FAP imaging agent PET/CT imaging in diagnosis of tumor; | — |
Countries
China
Contacts
Public ContactTang Ganghua
Nanfang Hospital, Southern Medical University
Outcome results
None listed